REFLECTION: A Clinical Practice Learning Program for Galleri®
← catalyst calendarSponsored by GRAIL, Inc. (industry) · GRAL — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
14,633actual
Sites
16
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-23 | actual | When the study began enrolling |
| Primary completion | 2025-09-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-01-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Early Detection of Cancer
- Cancer
Interventions
- Other: MCED
- Other: SOC
Primary outcome
what the primary-completion date above is the date OFTo describe signal detection and cancer detection within and across sites among participants who opt to receive Galleri® in a real world setting.
measured Up to 12 Months
Publications
- PMID 40207404 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GRAL's whole pipeline · Catalyst calendar · Every registered study · What changed